BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1036 related articles for article (PubMed ID: 23591280)

  • 1. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.
    Sagnelli E; Pisaturo M; Stanzione M; Messina V; Alessio L; Sagnelli C; Starace M; Pasquale G; Coppola N
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1174-1180.e11. PubMed ID: 23591280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.
    Liang CC; Liu CH; Chung CS; Lin CK; Su TH; Yang HC; Liu CJ; Chen PJ; Chen DS; Kao JH
    J Infect Dis; 2015 May; 211(9):1429-36. PubMed ID: 25387585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
    Carrión JA; Gonzalez-Colominas E; García-Retortillo M; Cañete N; Cirera I; Coll S; Giménez MD; Márquez C; Martin-Escudero V; Castellví P; Navinés R; Castaño JR; Galeras JA; Salas E; Bory F; Martín-Santos R; Solà R
    J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin.
    Viganò M; Aghemo A; Iavarone M; Rumi MG; Agnelli F; Lampertico P; Donato MF; Colombo M
    Antivir Ther; 2009; 14(6):789-96. PubMed ID: 19812441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.
    Cai Q; Chen F; Shao X; Zhang X; Zhao Z; Gao Z
    Antivir Ther; 2015; 20(2):217-24. PubMed ID: 25138110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA-negative patients are associated with virological relapse.
    Basso M; Giannini EG; Torre F; Blanchi S; Savarino V; Picciotto A
    Hepatology; 2009 May; 49(5):1442-8. PubMed ID: 19350657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
    Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation.
    Fernández I; Meneu JC; Colina F; García I; Muñoz R; Castellano G; Fuertes A; Abradelo M; Lumbreras C; Moreno E; Solís-Herruzo JA
    Liver Transpl; 2006 Dec; 12(12):1805-12. PubMed ID: 17133585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
    Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
    J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic fibrosis and serum alpha-fetoprotein (AFP) as predictors of response to HCV treatment and factors associated with serum AFP normalisation after treatment.
    El Raziky M; Attia D; El Akel W; Shaker O; Khatab H; Abdo S; Elsharkawy A; Esmat G
    Arab J Gastroenterol; 2013 Sep; 14(3):94-8. PubMed ID: 24206736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin.
    Zeuzem S; Rodríguez-Torres M; Rajender Reddy K; Marcellin P; Diago M; Craxi A; Pockros P; Rizzetto M; Bernstein D; Shiffman ML; Lin A; Tatsch F; Hadziyannis S
    J Viral Hepat; 2012 Nov; 19(11):766-74. PubMed ID: 23043383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peginterferon α-2a plus ribavirin in Latino and Non-Latino Whites with HCV genotype 1: Histologic outcomes and tolerability from the LATINO Study.
    Balart LA; Lisker-Melman M; Hamzeh FM; Kwok A; Lentz E; Rodriguez-Torres M;
    Am J Gastroenterol; 2010 Oct; 105(10):2177-85. PubMed ID: 20389293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin.
    Harada N; Hiramatsu N; Oze T; Morishita N; Yamada R; Hikita H; Miyazaki M; Yakushijin T; Miyagi T; Yoshida Y; Tatsumi T; Kanto T; Kasahara A; Oshita M; Mita E; Hagiwara H; Inui Y; Katayama K; Tamura S; Yoshihara H; Imai Y; Inoue A; Hayashi N; Takehara T
    J Viral Hepat; 2014 May; 21(5):357-65. PubMed ID: 24716638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained virological response: a milestone in the treatment of chronic hepatitis C.
    Morisco F; Granata R; Stroffolini T; Guarino M; Donnarumma L; Gaeta L; Loperto I; Gentile I; Auriemma F; Caporaso N
    World J Gastroenterol; 2013 May; 19(18):2793-8. PubMed ID: 23687416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
    Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
    Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
    Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin.
    Lange CM; von Wagner M; Bojunga J; Berg T; Farnik H; Hassler A; Sarrazin C; Herrmann E; Zeuzem S
    Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1303-7. PubMed ID: 20729742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of anti-viral therapy for occult hepatitis C virus infection.
    Pardo M; López-Alcorocho JM; Castillo I; Rodríguez-Iñigo E; Perez-Mota A; Carreño V
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1153-9. PubMed ID: 16611276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.